Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270.

Balasubramanian S, Fu Y, Pawashe M, et al. Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes. Nat Commun. 2017;8(1):382. doi:10.1038/s41467-017-00443-5.

Meier JA, Zhang F, Sanjana NE. GUIDES: sgRNA design for loss-of-function screens. Nat Methods. 2017;14(9):831-832. doi:10.1038/nmeth.4423.

Choi SH, Weng L-C, Roselli C, et al. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA. 2018;320(22):2354-2364. doi:10.1001/jama.2018.18179.

Hahn WC. A CRISPR Way to Identify Cancer Targets. N Engl J Med. 2019;380(25):2475-2477. doi:10.1056/NEJMcibr1905048.

Latva-Rasku A, Honka M-J, Stančáková A, et al. A Partial Loss-of-Function Variant in Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study. Diabetes. 2018;67(2):334-342. doi:10.2337/db17-1142.

Bobbili DR, Lal D, May P, et al. Exome-wide analysis of mutational burden in patients with typical and atypical Rolandic epilepsy. Eur J Hum Genet. 2018;26(2):258-264. doi:10.1038/s41431-017-0034-x.

Nicolas A, Kenna KP, Renton AE, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97(6):1268-1283.e6. doi:10.1016/j.neuron.2018.02.027.

Heinzen EL, O’Neill AC, Zhu X, et al. De novo and inherited private variants in MAP1B in periventricular nodular heterotopia. PLoS Genet. 2018;14(5):e1007281. doi:10.1371/journal.pgen.1007281.